New exosome production scale-up data presented
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes will be presented today at a leading US forum on the manufacture of cell and gene therapies.
Dr Nicola Goddard of the Department of Biochemical Engineering, University College London, will present new data from a grant-funded collaboration between ReNeuron, UCL and the Cell and Gene Therapy Catapult at the ECI Advancing Manufacture of Cell and Gene Therapies VI conference in Coronado, California. The new data demonstrate the feasibility of scaling up the production of ReNeuron’s CTX-derived exosomes utilising state-of-the-art bioreactor systems, representing a significant advance towards an industrial scale production process without affecting the quality and consistency of the final product.
The ongoing collaboration is part-funded by a grant from Innovate UK, the UK’s innovation agency.
Further information about the ECI conference can be found at https://buchanan.enablecloud.co.uk/index.php?entryPoint=campaign_trackerv2&track=3aa11ec0-252b-11e9-9dc0-18a9055a64ec&identifier=c1344502-252b-11e9-b58a-001a4bbe9414
Commenting on the new data, Dr Randolph Corteling, Head of Research at ReNeuron, said: “Exosomes are biological nanoparticles ideally suited to the delivery of oligonucleotide and gene-based therapies due to their natural occurrence and abundance, their ability to protect their cargo from degradation, and their potential for favourable bio-distribution. The ability to scale-up production of our CTX-derived exosomes, as demonstrated by these new results, further exemplifies the capability of ReNeuron’s exosome platform.”